| Literature DB >> 35634489 |
Sida Zhao1, Yue He1, Hongyun Wang1, Dan Li1, Lei Gong1, Yazhuo Zhang1,2, Chuzhong Li3.
Abstract
Ubiquitination is reported to be a critical biological event on ACTH secretion in corticotroph adenomas. However, the effect of ubiquitylation on ACTH secretion in silent corticotroph adenomas (SCAs) remains unclear. The aim of our study was to explore the mechanism of decreased secretion of ACTH in SCAs with ubiquitinomics. The differently expressed ubiquitinated proteins between SCAs and functioning corticotroph adenomas (FCAs) were identified by 4D label-free mass spectrometer, followed by bioinformatics analysis. The function of the candidate ubiquitinated protein ATP7A (K333) was validated in AtT20 cells. A total of 111 ubiquitinated sites corresponding to 94 ubiquitinated proteins were typically different between SCAs and FCAs. Among all the ubiquitinated sites, 102 showed decreased ubiquitination in SCAs, which mapped to 85 ubiquitinated proteins. Pathway enrichment analysis revealed that ubiquitinated proteins were mainly enriched in vesicle pathway and protein secretion pathway. ATP7A (K333) was one of the proteins enriched in vesicle pathway and protein secretion pathway with decreased ubiquitination level in SCAs. In vitro assay indicated that both ATP7A siRNA and omeprazole (ATP7A protein inhibitor) increased the secretion of ACTH in AtT20 cell supernatant compared to control groups (p<0.05). These results indicated that ATP7A might be related to the abnormal expression of ACTH in SCAs and potential for the treatment of SCAs.Entities:
Keywords: ACTH; ATP7A; mass spectrum; silent corticotroph adenomas; ubiquitination
Mesh:
Substances:
Year: 2022 PMID: 35634489 PMCID: PMC9130458 DOI: 10.3389/fendo.2022.863017
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1Characteristics of the identified ubiquitinated peptides between SCAs and FCAs. (A) The number of differently expressed ubiquitinated peptides and proteins. (B) Distribution of ubiquitinated peptides with different length. (C) Distribution of ubiquitinated proteins based on the number of ubiquitination sites.
Figure 2Representative ubiquitinated peptide spectrum: 333K*AIEAVSPGLYR344 (m/z=709.39) from ATP7A (Protein Session: Q04656), K* = ubiquitinated lysine residue.
Figure 3Motif analysis of differently expressed ubiquitination sites. (A) Potential ubiquitin recognition motif logos. The height of each letter represents the frequency of the residue in that position. K in the middle represent for the ubiquitinated lysine. (B) The number of identified peptides among the three motifs. (C) The heatmap for the amino acid distribution flanking ubiquitination sites.
Figure 4Enrichment analysis of GO annotations in identified ubiquitinated proteins (top 10). (A) Cell component. (B) Biological process. (C) Molecular function. GO, Gene Ontology.
Figure 5Pathway enrichment analysis of KEGG and GSEA with identified differently expressed ubiquitinated proteins (top 10). (A) Pathways by KEGG. (B) Pathways by GSEA.
Ubiquitinated proteins enriched in protein secretion pathway by GSEA.
| Gene name | S/F Ratio | S/F P value | Regulated Type |
|---|---|---|---|
| EGFR | 0.32 | 0.03 | Down |
| EGFR | 0.38 | 0.01 | Down |
| EGFR | 0.13 | 0.00 | Down |
| EGFR | 0.30 | 0.02 | Down |
| EGFR | 0.24 | 0.03 | Down |
| EGFR | 0.23 | 0.01 | Down |
| CLTC | 0.39 | 0.02 | Down |
| ATP7A | 0.17 | 0.05 | Down |
| AP2S1 | 0.20 | 0.01 | Down |
| RER1 | 0.11 | 0.04 | Down |
| ERGIC3 | 0.25 | 0.01 | Down |
Figure 6Protein–protein interaction (PPI) network in SCAs.
Proteins interacted with POMC.
| #node1 | node2 | coexpression | database_annotated | automated_textmining | combined_score |
|---|---|---|---|---|---|
| POMC | GNAO1 | 0.062 | 0.6 | 0.175 | 0.663 |
| POMC | ATP7A | 0 | 0 | 0.726 | 0.726 |
| POMC | ATP6AP1 | 0 | 0 | 0.508 | 0.508 |
| POMC | CHGB | 0 | 0 | 0.427 | 0.426 |
| POMC | PRKAR1A | 0 | 0 | 0.602 | 0.602 |
Figure 7Function of ATP7A in AtT20 cells. (A) The intensity of ubiquitinated peptides of ATP7A in SCAs and FCAs. (B) Up-regulation of the ACTH level in AtT20 cells with the knockdown of ATP7A by ATP7A siRNA. (C) Up-regulation of the ACTH level in AtT20 cells treated with 20uM omeprazole. All assays were performed in triplicate. (D) The top 20 potential E3 ligases of ATP7A. *Compared to control, p < 0.05.